GEMVAX Confirmed as Signature Sponsor of 'Neuro 2024'

Topline Results of Domestic Clinical Trials to Be Presented at October Conference in Toronto, Canada

GemVax & Kael announced on the 25th that it has confirmed its participation as a signature sponsor in the international research symposium on Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD), ‘Neuro2024’.

Additionally, the company plans to present the topline results of the domestic PSP Phase 2 clinical trial and hold a related briefing session at this conference.

‘Neuro2024’ is an annual academic conference where renowned neuroscience experts from various countries gather to present diverse research findings on PSP and CBD. It is hosted annually by CurePSP and will be held this year on October 24-25 in Toronto, Canada.

GemVax will participate as the main sponsor, the signature sponsor, to explain the results of the PSP clinical trial and exchange opinions with global opinion leaders in neurodegenerative diseases attending the conference. The company will also actively engage with PSP patients and their families to build a network.

CurePSP is a nonprofit charitable organization based in New York, USA, established in 1990, supporting disease awareness and treatment research for PSP, CBD, and Multiple System Atrophy (MSA). It provides community formation and information on diseases to patients and their families, and supports research funding and exchanges among researchers for professionals.

PSP is an atypical Parkinsonian syndrome that shows symptoms similar to Parkinson’s disease but progresses faster and currently has no fundamental treatment. The main symptoms include gait disturbance, postural instability, speech impairment, and ocular motor dysfunction, and the cause of onset is still unknown.

GemVax is conducting the first domestic PSP Phase 2 clinical trial and was designated as a ‘Developmental Stage Orphan Drug’ by the Ministry of Food and Drug Safety (MFDS) in February this year in relation to this.

The global PSP clinical trial is currently being prepared after receiving approval for the Phase 2 clinical trial plan from the U.S. Food and Drug Administration (FDA) in February.